In a filing, Verona Pharma Plc ADR revealed its Chief Medical Officer Rickard Kathleen A. unloaded Company’s shares for reported $0.66 million on Mar 12 ’25. In the deal valued at $8.35 per share,79,264 shares were sold. As a result of this transaction, Rickard Kathleen A. now holds 2,608,976 shares worth roughly $163.58 million.
Then, KATHLEEN RICKARD bought 9,908 shares, generating $621,232 in total proceeds.
Before that, ZACCARDELLI DAVID sold 640,264 shares. Verona Pharma Plc ADR shares valued at $3,205,226 were divested by the President and CEO at a price of $5.01 per share. As a result of the transaction, ZACCARDELLI DAVID now holds 14,367,552 shares, worth roughly $900.85 million.
ROTH MKM initiated its Verona Pharma Plc ADR [VRNA] rating to a Buy in a research note published on January 10, 2025; the price target was $68. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early October with a ‘”an Overweight”‘ rating.
Price Performance Review of VRNA
On Friday, Verona Pharma Plc ADR [NASDAQ:VRNA] saw its stock fall -2.81% to $62.70. Over the last five days, the stock has lost -6.15%. Verona Pharma Plc ADR shares have risen nearly 35.01% since the year began. Nevertheless, the stocks have risen 288.48% over the past one year. While a 52-week high of $70.40 was reached on 03/03/25, a 52-week low of $11.39 was recorded on 01/10/25. SMA at 50 days reached $61.99, while 200 days put it at $38.50.
Levels Of Support And Resistance For VRNA Stock
The 24-hour chart illustrates a support level at 61.66, which if violated will result in even more drops to 60.62. On the upside, there is a resistance level at 64.08. A further resistance level may holdings at 65.45. The Relative Strength Index (RSI) on the 14-day chart is 47.10, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.25, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 64.91%. Stochastics %K at 47.19% indicates the stock is a holding.
How much short interest is there in Verona Pharma Plc ADR?
A steep rise in short interest was recorded in Verona Pharma Plc ADR stocks on 2025-03-14, growing by 2.06 million shares to a total of 9.85 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 7.78 million shares. There was a rise of 20.96%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 26, 2022 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $31 price target.
